BIOSOLVE-IV study confirms excellent safety, efficacy profile of Biotronik’s Magmaris Resorbable Magnesium Scaffold
Biotronik presented data from the full-cohort 2-year BIOSOLVE-IV study in a poster session at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2022. Principal investigator Prof. Dr Johan Bennett presented the recent findings and highlighted the low TLF rate and the low scaffold thrombosis rate of Magmaris Resorbable Magnesium Scaffold (RMS).
Magmaris is the first resorbable magnesium scaffold (RMS) approved to treat de novo coronary artery lesions by percutaneous coronary angioplasty. Throughout various studies, Magmaris RMS shows confirmed clinical safety and efficacy. At 12 months after implantation, magnesium resorption is almost complete. This may help prevent scaffold thrombosis, a potentially dangerous complication.
“Our latest clinical results show a continuation of previous study data and prove that Magmaris RMS has an excellent safety and efficacy profile up to 24 months with TLF rates comparable to contemporary available drug eluting stents,” said Prof. Bennett, Coronary Interventionalist at University Hospitals Leuven, Leuven, Belgium.
The PMS registry enrolled 2,066 patients worldwide with a large amount of complex patient groups including N-STEMI (18.5%) and diabetic (21.6%) patients as well as cases with B2/C lesions (15.2%) and bifurcation lesions (4.6%).
“As the only magnesium based resorbable scaffold technology, the Magmaris scaffold is a unique tool providing a completely different clinical profile to other resorbable technologies. Magmaris has consistently shown excellent outcomes in clinical studies including the latest 24-month data from this large ‘real world’ registry as well as longer term data from previous studies,” noted Dr. Jörg Pochert, President Vascular Intervention at Biotronik. “In addition, the latest data from our next generation RMS also presented at TCT indicates that resorbable magnesium scaffolds may well be the future of resorbable technology.”
The BIOSOLVE-IV study examines the clinical performance and safety of the Magmaris RMS up to a five-year follow-up and is expected to run until 2025.
For more information, visit: http://www.magmaris.com/en
